{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:29:07Z","timestamp":1791386947464,"version":"4.3.3"},"reference-count":68,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:00:00Z","timestamp":1661644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/00090"],"award-info":[{"award-number":["PI16\/00090"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/01266"],"award-info":[{"award-number":["PI19\/01266"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/00145"],"award-info":[{"award-number":["PI15\/00145"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/0358"],"award-info":[{"award-number":["PI18\/0358"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00768"],"award-info":[{"award-number":["PI18\/00768"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI-0198-2016"],"award-info":[{"award-number":["PI-0198-2016"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FPU17\/00026"],"award-info":[{"award-number":["FPU17\/00026"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["EST19\/01091"],"award-info":[{"award-number":["EST19\/01091"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI044031"],"award-info":[{"award-number":["PI044031"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Consejer\u00eda de Igualdad, Salud y Pol\u00edticas Sociales","award":["PI16\/00090"],"award-info":[{"award-number":["PI16\/00090"]}]},{"name":"Consejer\u00eda de Igualdad, Salud y Pol\u00edticas Sociales","award":["PI19\/01266"],"award-info":[{"award-number":["PI19\/01266"]}]},{"name":"Consejer\u00eda de Igualdad, Salud y Pol\u00edticas Sociales","award":["PI15\/00145"],"award-info":[{"award-number":["PI15\/00145"]}]},{"name":"Consejer\u00eda de Igualdad, Salud y Pol\u00edticas Sociales","award":["PI18\/0358"],"award-info":[{"award-number":["PI18\/0358"]}]},{"name":"Consejer\u00eda de Igualdad, Salud y Pol\u00edticas Sociales","award":["PI18\/00768"],"award-info":[{"award-number":["PI18\/00768"]}]},{"name":"Consejer\u00eda de Igualdad, Salud y Pol\u00edticas Sociales","award":["PI-0198-2016"],"award-info":[{"award-number":["PI-0198-2016"]}]},{"name":"Consejer\u00eda de Igualdad, Salud y Pol\u00edticas Sociales","award":["FPU17\/00026"],"award-info":[{"award-number":["FPU17\/00026"]}]},{"name":"Consejer\u00eda de Igualdad, Salud y Pol\u00edticas Sociales","award":["EST19\/01091"],"award-info":[{"award-number":["EST19\/01091"]}]},{"name":"Consejer\u00eda de Igualdad, Salud y Pol\u00edticas Sociales","award":["PI044031"],"award-info":[{"award-number":["PI044031"]}]},{"DOI":"10.13039\/501100003176","name":"FPU predoctoral fellowship","doi-asserted-by":"publisher","award":["PI16\/00090"],"award-info":[{"award-number":["PI16\/00090"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"FPU predoctoral fellowship","doi-asserted-by":"publisher","award":["PI19\/01266"],"award-info":[{"award-number":["PI19\/01266"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"FPU predoctoral fellowship","doi-asserted-by":"publisher","award":["PI15\/00145"],"award-info":[{"award-number":["PI15\/00145"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"FPU predoctoral fellowship","doi-asserted-by":"publisher","award":["PI18\/0358"],"award-info":[{"award-number":["PI18\/0358"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"FPU predoctoral fellowship","doi-asserted-by":"publisher","award":["PI18\/00768"],"award-info":[{"award-number":["PI18\/00768"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"FPU predoctoral fellowship","doi-asserted-by":"publisher","award":["PI-0198-2016"],"award-info":[{"award-number":["PI-0198-2016"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"FPU predoctoral fellowship","doi-asserted-by":"publisher","award":["FPU17\/00026"],"award-info":[{"award-number":["FPU17\/00026"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"FPU predoctoral fellowship","doi-asserted-by":"publisher","award":["EST19\/01091"],"award-info":[{"award-number":["EST19\/01091"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"FPU predoctoral fellowship","doi-asserted-by":"publisher","award":["PI044031"],"award-info":[{"award-number":["PI044031"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"GEIVEX Mobility Fellowships 2020","doi-asserted-by":"publisher","award":["PI16\/00090"],"award-info":[{"award-number":["PI16\/00090"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"GEIVEX Mobility Fellowships 2020","doi-asserted-by":"publisher","award":["PI19\/01266"],"award-info":[{"award-number":["PI19\/01266"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"GEIVEX Mobility Fellowships 2020","doi-asserted-by":"publisher","award":["PI15\/00145"],"award-info":[{"award-number":["PI15\/00145"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"GEIVEX Mobility Fellowships 2020","doi-asserted-by":"publisher","award":["PI18\/0358"],"award-info":[{"award-number":["PI18\/0358"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"GEIVEX Mobility Fellowships 2020","doi-asserted-by":"publisher","award":["PI18\/00768"],"award-info":[{"award-number":["PI18\/00768"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"GEIVEX Mobility Fellowships 2020","doi-asserted-by":"publisher","award":["PI-0198-2016"],"award-info":[{"award-number":["PI-0198-2016"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"GEIVEX Mobility Fellowships 2020","doi-asserted-by":"publisher","award":["FPU17\/00026"],"award-info":[{"award-number":["FPU17\/00026"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"GEIVEX Mobility Fellowships 2020","doi-asserted-by":"publisher","award":["EST19\/01091"],"award-info":[{"award-number":["EST19\/01091"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"GEIVEX Mobility Fellowships 2020","doi-asserted-by":"publisher","award":["PI044031"],"award-info":[{"award-number":["PI044031"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ISCIII","award":["PI16\/00090"],"award-info":[{"award-number":["PI16\/00090"]}]},{"name":"ISCIII","award":["PI19\/01266"],"award-info":[{"award-number":["PI19\/01266"]}]},{"name":"ISCIII","award":["PI15\/00145"],"award-info":[{"award-number":["PI15\/00145"]}]},{"name":"ISCIII","award":["PI18\/0358"],"award-info":[{"award-number":["PI18\/0358"]}]},{"name":"ISCIII","award":["PI18\/00768"],"award-info":[{"award-number":["PI18\/00768"]}]},{"name":"ISCIII","award":["PI-0198-2016"],"award-info":[{"award-number":["PI-0198-2016"]}]},{"name":"ISCIII","award":["FPU17\/00026"],"award-info":[{"award-number":["FPU17\/00026"]}]},{"name":"ISCIII","award":["EST19\/01091"],"award-info":[{"award-number":["EST19\/01091"]}]},{"name":"ISCIII","award":["PI044031"],"award-info":[{"award-number":["PI044031"]}]},{"DOI":"10.13039\/501100002704","name":"AECC","doi-asserted-by":"publisher","award":["PI16\/00090"],"award-info":[{"award-number":["PI16\/00090"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"AECC","doi-asserted-by":"publisher","award":["PI19\/01266"],"award-info":[{"award-number":["PI19\/01266"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"AECC","doi-asserted-by":"publisher","award":["PI15\/00145"],"award-info":[{"award-number":["PI15\/00145"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"AECC","doi-asserted-by":"publisher","award":["PI18\/0358"],"award-info":[{"award-number":["PI18\/0358"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"AECC","doi-asserted-by":"publisher","award":["PI18\/00768"],"award-info":[{"award-number":["PI18\/00768"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"AECC","doi-asserted-by":"publisher","award":["PI-0198-2016"],"award-info":[{"award-number":["PI-0198-2016"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"AECC","doi-asserted-by":"publisher","award":["FPU17\/00026"],"award-info":[{"award-number":["FPU17\/00026"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"AECC","doi-asserted-by":"publisher","award":["EST19\/01091"],"award-info":[{"award-number":["EST19\/01091"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"AECC","doi-asserted-by":"publisher","award":["PI044031"],"award-info":[{"award-number":["PI044031"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Background: Sorafenib constitutes a suitable treatment alternative for patients with advanced hepatocellular carcinoma (HCC) in whom atezolizumab + bevacizumab therapy is contraindicated. The aim of the study was the identification of a miRNA signature in liquid biopsy related to sorafenib response. Methods: miRNAs were profiled in hepatoblastoma HepG2 cells and tested in animal models, extracellular vesicles (EVs), and plasma from HCC patients. Results: Sorafenib altered the expression of 11 miRNAs in HepG2 cells. miR-200c-3p and miR-27a-3p exerted an anti-tumoral activity by decreasing cell migration and invasion, whereas miR-122-5p, miR-148b-3p, miR-194-5p, miR-222-5p, and miR-512-3p exerted pro-tumoral properties by increasing cell proliferation, migration, or invasion, or decreasing apoptosis. Sorafenib induced a change in EVs population with an increased number of larger EVs, and promoted an accumulation of miR-27a-3p, miR-122-5p, miR-148b-3p, miR-193b-3p, miR-194-5p, miR-200c-3p, and miR-375 into exosomes. In HCC patients, circulating miR-200c-3p baseline levels were associated with increased survival, whereas high levels of miR-222-5p and miR-512-3p after 1 month of sorafenib treatment were related to poor prognosis. The RNA sequencing revealed that miR-200c-3p was related to the regulation of cell growth and death, whereas miR-222-5p and miR-512-3p were related to metabolic control. Conclusions: The study showed that Sorafenib regulates a specific miRNA signature in which miR-200c-3p, miR-222-5p, and miR-512-3p bear prognostic value and contribute to treatment response.<\/jats:p>","DOI":"10.3390\/cells11172673","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T21:22:56Z","timestamp":1661721776000},"page":"2673","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"11","author":[{"given":"Patricia","family":"de la Cruz-Ojeda","sequence":"first","affiliation":[{"name":"Institute of Biomedicine of Seville (IBiS), Hospital University \u201cVirgen del Roc\u00edo\u201d\/CSIC\/University of Seville, 41013 Seville, Spain"},{"name":"Networked Biomedical Research Center Hepatic and Digestive Diseases (CIBEREHD), 28029 Madrid, Spain"},{"name":"Department of Medical Physiology and Biophysics, University of Seville, 41004 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1952-5259","authenticated-orcid":false,"given":"Tobias","family":"Schmid","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, 60528 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6015-3901","authenticated-orcid":false,"given":"Loreto","family":"Boix","sequence":"additional","affiliation":[{"name":"Networked Biomedical Research Center Hepatic and Digestive Diseases (CIBEREHD), 28029 Madrid, Spain"},{"name":"BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Moreno","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Hospital University \u201cVirgen del Roc\u00edo\u201d\/CSIC\/University of Seville\/IBIS, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4379-6486","authenticated-orcid":false,"given":"V\u00edctor","family":"Sapena","sequence":"additional","affiliation":[{"name":"BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Praena-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Statistics and Operations Research, University of Granada, 18011 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Castell","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hospital University \u201cVirgen del Roc\u00edo\u201d\/CSIC\/University of Seville\/IBIS, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3133-0670","authenticated-orcid":false,"given":"Juan Manuel","family":"Falc\u00f3n-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Networked Biomedical Research Center Hepatic and Digestive Diseases (CIBEREHD), 28029 Madrid, Spain"},{"name":"Exosomes Lab, CIC bioGUNE, 48160 Derio, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5711-9534","authenticated-orcid":false,"given":"Mar\u00eda","family":"Reig","sequence":"additional","affiliation":[{"name":"Networked Biomedical Research Center Hepatic and Digestive Diseases (CIBEREHD), 28029 Madrid, Spain"},{"name":"BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8237-2841","authenticated-orcid":false,"given":"Bernhard","family":"Br\u00fcne","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, 60528 Frankfurt, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Frankfurt, 60528 Frankfurt, Germany"},{"name":"Frankfurt Cancer Institute, Goethe-University Frankfurt, 60528 Frankfurt, Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, 60528 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5155-3508","authenticated-orcid":false,"given":"Miguel A.","family":"G\u00f3mez-Bravo","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Hospital University \u201cVirgen del Roc\u00edo\u201d\/CSIC\/University of Seville\/IBIS, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6849-9272","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Gir\u00e1ldez","sequence":"additional","affiliation":[{"name":"Unit for the Clinical Management of Digestive Diseases, Hospital University \u201cVirgen del Roc\u00edo\u201d\/CSIC\/University of Seville\/IBIS, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Bruix","sequence":"additional","affiliation":[{"name":"Networked Biomedical Research Center Hepatic and Digestive Diseases (CIBEREHD), 28029 Madrid, Spain"},{"name":"BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3453-4038","authenticated-orcid":false,"given":"Mar\u00eda T.","family":"Ferrer","sequence":"additional","affiliation":[{"name":"Unit for the Clinical Management of Digestive Diseases, Hospital University \u201cVirgen del Roc\u00edo\u201d\/CSIC\/University of Seville\/IBIS, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-1121","authenticated-orcid":false,"given":"Jordi","family":"Muntan\u00e9","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine of Seville (IBiS), Hospital University \u201cVirgen del Roc\u00edo\u201d\/CSIC\/University of Seville, 41013 Seville, Spain"},{"name":"Networked Biomedical Research Center Hepatic and Digestive Diseases (CIBEREHD), 28029 Madrid, Spain"},{"name":"Department of Medical Physiology and Biophysics, University of Seville, 41004 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and surveillance for hepatocellular carcinoma: New trends","volume":"72","author":"Singal","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","article-title":"Systemic treatment of hepatocellular carcinoma: An EASL position paper","volume":"75","author":"Bruix","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/liv.14223","article-title":"Biology and significance of alpha-fetoprotein in hepatocellular carcinoma","volume":"39","author":"Galle","year":"2019","journal-title":"Liver Int."},{"key":"ref_6","unstructured":"European Association for the Study of the Liver (2018). Electronic address: Easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2009.04.005","article-title":"Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma","volume":"137","author":"Marrero","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-11-2175","article-title":"Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Pinero, F., Dirchwolf, M., and Pessoa, M.G. (2020). Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells, 9.","DOI":"10.3390\/cells9061370"},{"key":"ref_10","first-page":"3610","article-title":"A six-miRNA signature as a novel biomarker for improving prediction of prognosis and patterns of immune infiltration in hepatocellular carcinoma","volume":"14","author":"Chen","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"825261","DOI":"10.3389\/fgene.2022.825261","article-title":"Construction of a Necroptosis-Related miRNA Signature for Predicting the Prognosis of Patients With Hepatocellular Carcinoma","volume":"13","author":"Meng","year":"2022","journal-title":"Front. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Chen, Z., Lin, X., Wan, Z., Xiao, M., Ding, C., Wan, P., Li, Q., and Zheng, S. (2022). High Expression of EZH2 Mediated by ncRNAs Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma. Genes, 13.","DOI":"10.3390\/genes13050876"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hu, S., Zhang, J., Guo, G., Zhang, L., Dai, J., and Gao, Y. (2022). Comprehensive analysis of GSEC\/miR-101-3p\/SNX16\/PAPOLG axis in hepatocellular carcinoma. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0267117"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41420-021-00787-4","article-title":"LncRNA LINC00667 aggravates the progression of hepatocellular carcinoma by regulating androgen receptor expression as a miRNA-130a-3p sponge","volume":"7","author":"Qin","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7150\/ijbs.66915","article-title":"CircCCNB1 silencing acting as a miR-106b-5p sponge inhibited GPM6A expression to promote HCC progression by enhancing DYNC1I1 expression and activating the AKT\/ERK signaling pathway","volume":"18","author":"Liu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1136\/gutjnl-2019-320282","article-title":"Liquid biopsy in the clinical management of hepatocellular carcinoma","volume":"69","author":"Schulze","year":"2020","journal-title":"Gut"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41419-021-03827-0","article-title":"Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity","volume":"12","author":"Davalillo","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1053\/j.gastro.2019.01.261","article-title":"Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma","volume":"156","author":"Teufel","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_19","first-page":"283","article-title":"Human hepatocyte culture","volume":"320","author":"Pichard","year":"2006","journal-title":"Methods Mol. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.humpath.2009.07.003","article-title":"Hep G2 is a hepatoblastoma-derived cell line","volume":"40","author":"Cheung","year":"2009","journal-title":"Hum. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Sherman","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: Ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","article-title":"The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets","volume":"49","author":"Szklarczyk","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_28","first-page":"692","article-title":"Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells","volume":"234","author":"Gonzalez","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13046-016-0430-z","article-title":"Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro","volume":"35","author":"Qu","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e11200","DOI":"10.7717\/peerj.11200","article-title":"Cisplatin-resistant HepG2 cell-derived exosomes transfer cisplatin resistance to cisplatin-sensitive cells in HCC","volume":"9","author":"Tang","year":"2021","journal-title":"PeerJ"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: Genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ajpath.2017.10.024","article-title":"A Large Set of miRNAs Is Dysregulated from the Earliest Steps of Human Hepatocellular Carcinoma Development","volume":"188","author":"Sulas","year":"2018","journal-title":"Am. J. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1038\/onc.2011.500","article-title":"MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo","volume":"31","author":"He","year":"2012","journal-title":"Oncogene"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1038\/onc.2009.211","article-title":"Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties","volume":"28","author":"Coulouarn","year":"2009","journal-title":"Oncogene"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1080\/22221751.2022.2037393","article-title":"Human hepatocyte-enriched miRNA-192-3p promotes HBV replication through inhibiting Akt\/mTOR signalling by targeting ZNF143 in hepatic cell lines","volume":"11","author":"Li","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.lfs.2016.04.037","article-title":"Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes","volume":"156","author":"Krattinger","year":"2016","journal-title":"Life Sci."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kiamehr, M., Heiskanen, L., Laufer, T., Dusterloh, A., Kahraman, M., Kakela, R., Laaksonen, R., and Aalto-Setala, K. (2019). Dedifferentiation of Primary Hepatocytes is Accompanied with Reorganization of Lipid Metabolism Indicated by Altered Molecular Lipid and miRNA Profiles. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20122910"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2147\/OTT.S232453","article-title":"Exosomal MicroRNAs as Liquid Biopsy Biomarkers in Hepatocellular Carcinoma","volume":"13","author":"Wang","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Manganelli, M., Grossi, I., Ferracin, M., Guerriero, P., Negrini, M., Ghidini, M., Senti, C., Ratti, M., Pizzo, C., and Passalacqua, R. (2021). Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib. Biomedicines, 9.","DOI":"10.3390\/biomedicines9070813"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/ijc.32543","article-title":"Extracellular vesicles transmitted miR-31-5p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma","volume":"146","author":"He","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1158\/1078-0432.CCR-16-1464","article-title":"In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis","volume":"23","author":"Fornari","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1158\/0008-5472.CAN-19-0472","article-title":"MiR-30e-3p Influences Tumor Phenotype through MDM2\/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma","volume":"80","author":"Gramantieri","year":"2020","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3892\/ol.2020.11696","article-title":"Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma","volume":"20","author":"Kohno","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Ji, X., Liu, K., Shi, Y., Wang, C., Li, Y., Zhang, T., He, Y., Xiang, M., and Zhao, R. (2020). Exosomal miR-200c-3p negatively regulates the migration and invasion of lipopolysaccharide (LPS)-stimulated colorectal cancer (CRC). BMC Mol. Cell Biol., 21.","DOI":"10.1186\/s12860-020-00291-0"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Raue, R., Frank, A.C., Fuhrmann, D.C., de la Cruz-Ojeda, P., Rosser, S., Bauer, R., Cardamone, G., Weigert, A., Syed, S.N., and Schmid, T. (2022). MicroRNA-200c Attenuates the Tumor-Infiltrating Capacity of Macrophages. Biology, 11.","DOI":"10.3390\/biology11030349"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12935-017-0500-0","article-title":"MicroRNA 200c-3p regulates autophagy via upregulation of endoplasmic reticulum stress in PC-3 cells","volume":"18","author":"Sohn","year":"2018","journal-title":"Cancer Cell Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"101528","DOI":"10.1016\/j.redox.2020.101528","article-title":"Downregulation of thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer","volume":"34","author":"Gonzalez","year":"2020","journal-title":"Redox Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/hep.28574","article-title":"Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis","volume":"64","author":"Sun","year":"2016","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/onc.2009.504","article-title":"Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver","volume":"29","author":"Wu","year":"2010","journal-title":"Oncogene"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1021\/acs.jproteome.9b00821","article-title":"Proto-Oncogene Serine\/Threonine Kinase PIM3 Promotes Cell Migration via Modulating Rho GTPase Signaling","volume":"19","author":"Dang","year":"2020","journal-title":"J. Proteome Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"72652","DOI":"10.18632\/oncotarget.20194","article-title":"Ubenimex suppresses Pim-3 kinase expression by targeting CD13 to reverse MDR in HCC cells","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/1078-0432.CCR-09-1840","article-title":"MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling","volume":"16","author":"Wong","year":"2010","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3892\/ijo.2014.2577","article-title":"miR222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma","volume":"45","author":"Liu","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Lee, H.Y., Nga, H.T., Tian, J., and Yi, H.S. (2021). Mitochondrial Metabolic Signatures in Hepatocellular Carcinoma. Cells, 10.","DOI":"10.3390\/cells10081901"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/sj.bjc.6601838","article-title":"Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular carcinoma","volume":"90","author":"Yin","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Zhou, X., Shen, H., Wang, D., and Wang, Y. (2009). Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: Evidence from an in vitro study. BMC Med., 7.","DOI":"10.1186\/1741-7015-7-41"},{"key":"ref_57","first-page":"3231273","article-title":"Low UGP2 Expression Is Associated with Tumour Progression and Predicts Poor Prognosis in Hepatocellular Carcinoma","volume":"2020","author":"Hu","year":"2020","journal-title":"Dis. Mark."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"797102","DOI":"10.3389\/fcell.2021.797102","article-title":"ENO3 Inhibits Growth and Metastasis of Hepatocellular Carcinoma via Wnt\/beta-Catenin Signaling Pathway","volume":"9","author":"Cui","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Liu, Y., Jiang, G., Lv, C., and Yang, C. (2021). miR-222-5p promotes dysfunction of human vascular smooth muscle cells by targeting RB1. Environ. Toxicol.","DOI":"10.1002\/tox.23434"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2021.11.010","article-title":"Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis","volume":"76","author":"Liu","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/carcin\/bgs113","article-title":"MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma","volume":"33","author":"Wang","year":"2012","journal-title":"Carcinogenesis"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1476-4598-10-52","article-title":"Micro-RNA expression in cisplatin resistant germ cell tumor cell lines","volume":"10","author":"Port","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41419-021-04370-8","article-title":"MRPS31 loss is a key driver of mitochondrial deregulation and hepatocellular carcinoma aggressiveness","volume":"12","author":"Min","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.18632\/oncotarget.2549","article-title":"Clinical significance and therapeutic value of glutathione peroxidase 3 (GPx3) in hepatocellular carcinoma","volume":"5","author":"Qi","year":"2014","journal-title":"Oncotarget"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbt.22767","article-title":"Exosomal miR-512-3p derived from mesenchymal stem cells inhibits oxidized low-density lipoprotein-induced vascular endothelial cells dysfunction via regulating Keap1","volume":"35","author":"Chen","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"57707","DOI":"10.18632\/oncotarget.17202","article-title":"The role of autophagy in hepatocellular carcinoma: Friend or foe","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/2211-5463.12043","article-title":"SNAI1 promotes the development of HCC through the enhancement of proliferation and inhibition of apoptosis","volume":"6","author":"Qi","year":"2016","journal-title":"FEBS Open Bio"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/onc.2016.237","article-title":"Cadherin-6 promotes EMT and cancer metastasis by restraining autophagy","volume":"36","author":"Gugnoni","year":"2017","journal-title":"Oncogene"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/17\/2673\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:19:08Z","timestamp":1760141948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/17\/2673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,28]]},"references-count":68,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["cells11172673"],"URL":"https:\/\/doi.org\/10.3390\/cells11172673","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,28]]}}}